GSK’s $10.6 Billion Acquisition of Nuvalent Sparks 39% Stock Surge

GSK has agreed to acquire Nuvalent for $10.6 billion in an all-cash deal, offering $124 per share—a 40% premium over Monday's closing price. Nuvalent's stock surged 39% to $122.90 in early trading Tuesday, reflecting investor enthusiasm for the transaction.

The deal grants GSK three non-small cell lung cancer programs, including zidesamtinib and neladalkib, both under FDA review with decisions expected in late 2026. A third asset, NVL-330, is in phase I trials. Analysts highlight the lead products as potential best-in-class therapies, with near-term commercialization prospects if approved.

This marks GSK's largest acquisition in over a decade, signaling a strategic pivot toward oncology innovation. The London-listed pharma giant's shares dipped 3% on the announcement, while its ADRs remained flat at $50.65.